The Insurer Whose Superpower Is Saying No

Most investors test pricing power the same way: can the company raise its price and keep the customer? Nick Sleep, in a 2004 letter to his Nomad Investment Partnership investors, described a company that never raises its price at all. It just refuses to sell — for years, if it has to — until the price is right.

The company was National Indemnity, an insurance subsidiary of Berkshire Hathaway. Its business is underwriting risk, and its version of pricing power isn't a number on a rate card. It's a decision to write nothing.

The unexpected part

Here's the fact that breaks the standard model: Sleep records National Indemnity's willingness to let its own revenue fall 80% and stay there for years, rather than underwrite insurance at a price it considers wrong.

At National Indemnity (an insurance subsidiary of Berkshire Hathaway), the firm's ability to write insurance only when pricing is good and stand back when pricing is poor, even if revenues decline by 80% and remain depressed for many years, is a wonderful example of capital discipline and good capital allocation.

An 80% revenue decline, held for multiple years, on purpose. Most managements would call that a crisis. Sleep calls it the point.

The concrete part

Sit inside that decision for a moment, because the hard part isn't the strategy — it's living with it.

An insurer's product has no shelf. Nobody walks past it and notices the price is too high. The only way the market finds out National Indemnity thinks pricing is bad is that the company simply stops showing up to write policies, quarter after quarter, while premium volume — and the revenue line every other insurer in the market is reporting — collapses.

Sleep names exactly where the pressure to reverse course comes from, in the same letter: "from within the company (reinforced by poorly constructed incentive compensation), Wall Street promoters and short-term shareholders." Underwriters want to underwrite. Sales teams want a book to sell. Analysts want growth to model. Every one of those forces pushes toward writing the bad policy just to keep the number from falling further — and National Indemnity's answer, sustained for years, is still no.

That's the trait Sleep is actually screening for. His list of "super high-quality thinkers" — companies whose capital allocation he trusts enough to let them compound his money without interference — has one entry requirement above the rest: the willingness to shrink, or sit still, rather than deploy capital badly. "Why grow," he writes, "if returns are going to be poor?"

The credible part

A year later, in the June 2005 letter, Sleep applies the identical idea to a business that has nothing else in common with a Nebraska insurer: a cement plant in Zimbabwe.

Zimcem was, at the time, the country's largest cement producer — roughly 700,000 tons of capacity, no debt, a replacement cost Sleep put at $70–100 million. Zimbabwe's economy was in collapse. And the Harare stock exchange priced the company at one-seventieth of that replacement cost.

Sleep's name for this is "deep discount to replacement cost with latent pricing power" — a second, distinct model from the Costco-style "scale economies shared" idea Nomad is better known for. The logic: a cement plant eventually has to charge a price high enough to fund the capital it takes to replace its own machinery. If it doesn't, nobody builds new cement plants, supply stays flat or shrinks, and eventually the price has nowhere to go but up to the level that justifies replacement. The pricing power is real. It just isn't visible in the number on the invoice yet.

Sleep offers two proof points that the model already paid off elsewhere: Siam Cement, bought during the Asian crisis, rose twenty-fold from its trough within eight years. Pretoria Portland Cement, across the border in South Africa, went from $20 per ton of capacity in 1998 to $180 per ton by the time of the letter — a ninefold re-rating on the same underlying asset, once the market repriced the replacement cost rather than the depressed current one.

Two businesses, two continents, one idea underneath both: the price you can currently charge and the price the asset's economics actually support are different things, and the gap between them is where the return lives — if you're willing to wait for it.

Why this should bother you, specifically

Here is the uncomfortable part for anyone reading this with a portfolio open in another tab: both of Sleep's examples ask the investor to hold a position that looks, for a long stretch, like a mistake.

National Indemnity's shareholders had to watch four straight years of a shrinking top line with no promise of when it would turn. Zimcem's owners had to hold a stake in a business priced by a market that might never re-rate it — Sleep says so himself, flagging "confiscation events" in Zimbabwe as a real, non-zero risk to the whole thesis, not a footnote. Restraint isn't a free option. It costs revenue you can see today, in exchange for a price you can only argue exists.

That is the actual test this desk keeps returning to, framed a different way each time: is a company's discipline evidence of a moat, or is it just a bet on patience with a good story attached? Sleep never fully resolves it for either name — he holds the position anyway, and says why.

Back to the insurer

Return to National Indemnity's decision one more time, with the Zimcem model sitting next to it. The insurer isn't just being careful. It's making the same wager Sleep made on the cement plant: that a price which looks wrong today is temporary, and the discipline to refuse it is what makes the eventual right price worth having.

Pricing power, on this reading, was never about what a company charges when times are good. It's about what it's willing to walk away from when they aren't — and whether it can survive its own shareholders' patience running out before the price comes back.

Educational research, not investment advice. Every quote above is drawn verbatim from the Nomad Investment Partnership's own letters to investors and checked against the primary source. This is a framework and history piece, not commentary on any current security. No buy/sell recommendations, no price targets. Moat & Margin is not a SEBI-registered Research Analyst or Investment Adviser.